Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

542.27 USD +8.38 (+1.57%)
Official Closing Price Updated: 5:34 PM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021, before the U.S.... 
From PR Newswire
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
From PR Newswire
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
From PR Newswire
New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the... 
From PR Newswire
Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. The presentation is scheduled for 8:20... 
From PR Newswire
Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
From PR Newswire
Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
Scott+Scott Continues Investigation of Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN 
From Business Wire News Releases
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presented at the American Society of Hematology (ASH) 2020... 
From PR Newswire
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
From GlobeNewswire News Releases
Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
From PR Newswire
Thinking about trading options or stock in Square, Twist Bioscience, Regeneron Pharmaceuticals, General Electric, or American Airlines?
InvestorsObserver issues critical PriceWatch Alerts for SQ, TWST, REGN, GE, and AAL. 
From PR Newswire
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
From PR Newswire
Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has been included on the highly selective Dow Jones Sustainability World Index (DJSI World) for the second consecutive year. In... 
From PR Newswire
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 
From PR Newswire
Regeneron Reports Third Quarter 2020 Financial and Operating Results
From PR Newswire
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual) – Friday, November 13, 2020
Join us as we discuss today’s pressing healthcare issues. 
From Business Wire News Releases
REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Require
From PR Newswire
Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
From PR Newswire
FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA)... 
From PR Newswire
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
From PR Newswire
Diabetic Eye Disease Devices Market 2020 Emerging Players, Growth Analysis and Precise Outlook - 2026
Harrisburg, NC -- (SBWIRE) -- 10/28/2020 -- Global Diabetic Eye Disease Devices Market recently Published Market Insights Reports with more than 100 industry informative desk and Figures spread through... 
From SBWire - Latest Press Releases
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 
From PR Newswire
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
From GlobeNewswire News Releases
Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
From PR Newswire
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN)
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharma, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN) 
From Business Wire News Releases
Monoclonal Antibodies (MAbS) Market : Facts, Figures and Analytical Insights 2020-2026
Harrisburg, NC -- (SBWIRE) -- 10/20/2020 -- The Monoclonal Antibodies (MAbS) Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts,... 
From SBWire - Latest Press Releases
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
Join us as we discuss today’s pressing healthcare issues. 
From Business Wire News Releases
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
From GlobeNewswire News Releases
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Recommendation based on pivotal trial that showed Dupixent plus topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearance, itch and health-related... 
From PR Newswire
Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.